Unlock this StockReport nowClick to Unlock

Hansa Biopharma AB Share Price

HNSA SEK174.9 1.6  0.9%

Relative Strength (%)
Volume Change (%)
10d v 3m
Price vs... (%)
52w High
50d MA
200d MA
Growth & Value
Margin of Safety (beta)
Screens Passed 1
Balance Sheet · Income Statement · Cashflow Financial Summary
Year End 31st Dec 2013 2014 2015 2016 2017 2018 TTM 2019E 2020E CAGR / Avg
Revenue SEKm
Operating Profit SEKm
Net Profit SEKm
EPS Reported SEK
EPS Normalised SEK
EPS Growth %
PE Ratio x
Operating Margin %
Op. Cashflow ps SEK
Capex ps SEK
Free Cashflow ps SEK
Dividend ps SEK
Dividend Growth %
Dividend Yield %
Dividend Cover x
Balance Sheet
Cash etc SEKm
Working Capital SEKm
Net Fixed Assets SEKm
Net Debt SEKm
Book Value SEKm
Average Shares m
Book Value ps SEK +61.8%

FINANCIAL BRIEF: For the six months ended 30 June 2019, Hansa Biopharma AB revenues increased 1% to SEK1.5M. Net loss increased 47% to SEK154.9M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Selling/General/Admin. Expense increase from SEK30.3M to SEK68M (expense), Research and development expenses increase of 17% to SEK88.1M (expense). more »

Health Trend
Bankruptcy Risk
  Earnings Manipulation Risk
Magic Formula Score
Other Ratios
Leverage (ttm) Total -Intang +Pension
Gross Gearing %
Net Gearing %
Cash / Assets %
Recent History
Latest interim period (ended 30th Jun '19) vs. prior year
Sales Growth %
EPS Growth %
3yr Compound Annual Growth Rate
Sales Growth %
EPS Growth %
DPS Growth %

Broker Forecasts
31st Dec 2019
31st Dec 2020

Price Target: SEK330
(+90.41% above Price)
Net Profit EPS DPS Net Profit EPS DPS
Est. Long Term Growth Rate: n/a (SEK) (SEK) (SEK) (SEK) (SEK) (SEK)
Consensus Estimate
1m Change
3m Change
3 brokers Broker Consensus Trend
Broker Recommendations for Hansa Biopharma AB
Recommendation:Strong SellSellHoldBuyStrong Buy
No. of Analysts: 0 0 1 1 2

Named Brokers and Analysts
RBC Capital Markets Zoe Karamanoli , B. Riley FBR, Inc. , SEB Equities , Kempen & Co Ingrid Gafanhao , Redeye Arvid Necander , Erik Penser , Chardan Capital Markets , EVERCORE ISI Maneka Mirchandaney , Rx Securities Samir Devani ,

Profile Summary

Hansa Biopharma AB, formerly Hansa Medical AB, is a Sweden-based biopharmaceutical company with focus on immunomodulatory enzymes for treatment and prevention of rare and severe autoimmune conditions and transplant rejection. The Company’s operations consist of research and development for drug discovery. The Company conducts several projects, among which primary are IdeS (Immunoglobulin G-degrading enzyme of Streptococcus pyogenes) and HBP-assay (Heparin Binding Protein-assay). IdeS’s goal is to enable transplantation that prevents antibody-mediated rejection. HBP-assay is a diagnostic method that aims to predict severe sepsis in patients with infectious disease symptoms. The Company’s patent portfolio consists of several patent families that geographically cover numerous jurisdictions, including the United States, Europe and Japan.

Directors: Ulf Wiinberg (CHM) 60, Soeren Tulstrup (PRE) 54, Donato Spota (CFO) , Christian Kjellman (SVP) 52, Henk Doude van Troostwijk (SVP) 54, Eva-Maria Joed (CAD) 50, Anne Safstrom Lanner (VPR) 50, Karin Aschan (VPR) 58, Vincenza Nigro (VPR) 56, Max Sakajja (VPR) 38, Mats Blom (DRC) 54, Eva Nilsagard (DRC) 55, Andreas Eggert (IND) 52, Anders Gersel Pedersen (IND) 67, Birgit Stattin Norinder (IND) 71,

No. of Employees: 60 No. of Shareholders: 12,495

Last Annual December 31st, 2018
Last Interim June 30th, 2019
Public Since October 17, 2007
Shares in Issue 40,026,107
Free Float 6.23m (15.6%)
Sector Healthcare
Industry Biotechnology & Medical Research
Exchange OMX Nordic Exchange Stockholm
Eligible for an ISA? a SIPP?

HNSA Share Price Performance HNSA Share Price Quote
1.6  0.9%
Traded 8:12am · Minimum 15 min delayed · NMS:

Latest HNSA News Announcements (delayed)

Upcoming HNSA Events

Recent ↓
Thursday 18th July, 2019
Q2 2019 Hansa Biopharma AB Earnings Call
Thursday 18th July, 2019
Q2 2019 Hansa Biopharma AB Earnings Release
Wednesday 29th May, 2019 (estimate)
Hansa Medical AB Annual Shareholders Meeting
Monday 20th May, 2019
Hansa Biopharma AB at UBS Global Healthcare Conference
Monday 29th April, 2019
Q1 2019 Hansa Biopharma AB Earnings Call
Friday 8th February, 2019
Q4 2018 Hansa Biopharma AB Earnings Call
Tuesday 27th November, 2018
Hansa Medical AB at Evercore ISI MedTools Conference
Thursday 1st November, 2018
Q3 2018 Hansa Medical AB Earnings Call
Thursday 27th September, 2018
Hansa Medical AB (publ) - Special Call
Thursday 19th July, 2018
Q2 2018 Hansa Medical AB Earnings Call
Tuesday 29th May, 2018
Hansa Medical AB Annual Shareholders Meeting
Wednesday 25th April, 2018
Q1 2018 Hansa Medical AB Earnings Call
Tuesday 13th March, 2018
Hansa Medical AB at Cowen Health care Conference

Use of our data service is subject to express Terms of Service. Please see our full site disclaimer for more details. In particular, it is very important to do your own research (DYOR) and seek professional advice before making any investment based on your own personal circumstances. Please note that the information, data and analysis contained within this stock report: (a) include the proprietary information of Stockopedia's third party licensors and Stockopedia; (b) should not be copied or redistributed except as specifically authorised; and (c) are not warranted to be complete, accurate or timely. You should independently research and verify any information that you find in this report. Stockopedia will not be liable in respect of any loss, trading or otherwise, that you may suffer arising out of such information or any reliance you may place upon it. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up. © Stockopedia 2019.

Should you buy HNSA

Access HNSA Analytics Now!

Let’s get you setup so you get the most out of our service
Done, Let's add some stocks
Brilliant - You've created a folio! Now let's add some stocks to it.

  • Apple (AAPL)

  • Shell (RDSA)

  • Twitter (TWTR)

  • Volkswagon AG (VOK)

  • McDonalds (MCD)

  • Vodafone (VOD)

  • Barratt Homes (BDEV)

  • Microsoft (MSFT)

  • Tesco (TSCO)
Save and show me my analysis